Dosing Study of Replagal in Patients With Fabry Disease

NCT00068107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Replagal

Sponsor

Baylor Research Institute

Collaborators

[object Object]